Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin).
Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin).
复制标题
使用新型胃肠道脂肪酶抑制剂 Ro 18-0647（四氢脂抑素）对人体进行初步研究。
DOI：
10.1093/ajcn/55.1.309s
复制
发表时间：
1992
期刊：
影响因子：
--
通讯作者：
D. Hartmann
中科院分区：
文献类型：
--
作者：
J B Hauptman;F S Jeunet;D. Hartmann
过量摄入膳食脂肪有助于肥胖和高脂血症的发展和维持。抑制胃肠道脂肪酶可通过防止甘油三酯水解来减少全身吸收的脂肪摄入量。Ro 18-0647是天然产物lipstatin的化学合成衍生物，可抑制胃肠道脂肪酶的作用。在人类中的初步研究表明，Ro 18-0647可以可靠地增加粪便脂肪排泄。Ro 18-0647在大多数正常志愿者和肥胖患者中的耐受性良好。必须进行进一步的研究，以确定是否可以通过使用这种新的药理学原理产生减肥或降低胆固醇的临床终点。
Excessive intake of dietary fat contributes to the development and maintenance of both obesity and hyperlipidemia. Inhibition of gastrointestinal lipases could decrease the amount of ingested fat that is absorbed systemically by preventing the hydrolysis of triglycerides. Ro 18-0647, a chemically synthesized derivative of the natural product lipstatin, inhibits the action of gastrointestinal lipases. Initial studies in humans have shown that Ro 18-0647 can reliably increase fecal fat excretion. Ro 18-0647 has also been shown to be well tolerated in the majority of normal volunteers and obese patients studied. Further research must be conducted to determine whether clinical endpoints of weight loss or cholesterol lowering can be produced by using this new pharmacologic principle.
DOI：
10.1073/pnas.82.13.4526
发表时间：
1985-07
影响因子：
11.1
作者：
D. Spady;J. Dietschy
通讯作者：
D. Spady;J. Dietschy